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Objective: Doxycycline has been shown to inhibit aneurysm formation in a rodent model of abdominal aortic aneurysm
(AAA). The doses necessary for this inhibition (6 mg/kg) are much higher than the standard antibiotic doses (1 to 1.5
mg/kg) used in humans. Because the side effects associated with doxycycline are dose related, whether patients would
tolerate doses that are four to six times higher than normal is unclear. Also unclear is whether the serum levels necessary
in these animal models can be safely achieved in patients. The purposes of this study were to determine the serum
concentrations necessary to inhibit aneurysm formation in a mouse model of AAA and to compare them with the plasma
concentrations in patients with AAA with a standard dose of doxycycline.
Methods: Four groups of 10 mice of C57BL/6 strain were given doxycycline (0, 10, 50, and 100 mg/kg) beginning at 7
weeks of age. At 8 weeks of age, the mice underwent AAA induction through bathing periadventitial aortic tissue with
0.25 mol/L CaCl2. Blood samples were taken 10 weeks after surgery to assess the levels of doxycycline. Aortic size was
measured at AAA induction and at death with a videomicrometer. Fourteen patients with diagnosed AAA were given 100
mg of doxycycline twice a day for at least 3 months. Blood samples to determine the plasma levels of the drug were taken
at 3 or 6 months. The circulating levels of doxycycline for mice and humans were assessed with high-performance liquid
chromatography.
Results: The changes in aortic size and circulating levels of doxycycline in the AAA murine model are reported. Doses of
10, 50, and 100 mg/kg accounted for a 33%, 44%, and 66% reduction of the aneurysmal growth in the mice, respectively.
In patients, the circulating doxycycline levels ranged from 1.8 to 9.42 g/mL (mean, 4.14  0.557), values similar to
those obtained in mice.
Conclusion: The circulating doxycycline levels of the patients are comparable with those achieved in mice. Doxycycline
accounts for an inhibition of 33% to 66% of the aortic growth. The findings suggest that standard doxycycline doses could
inhibit AAA growth in humans. (J Vasc Surg 2002;35:923-9.)
Abdominal aortic aneurysms (AAAs) are a common
and life-threatening condition. The natural history of AAA
is one of progressive expansion. The rate of aneurysm
growth and the risk of rupture both are exponentially
related to aneurysm size. Aortic diameter is therefore the
single best predictor of rupture risk.1 Ninety-five percent of
aortic aneurysms occur in the aortic segment below the
renal arteries; the normal aortic diameter at this level is 2.0
to 2.5 cm, and risk of aneurysm rupture is low until aortic
diameter increases beyond 5.5 cm.2,3 AAAs are typically
asymptomatic and are therefore often undetected until late
in their natural history, when the weakened aortic wall is
prone to rupture. Spontaneous rupture of an aortic aneu-
rysm is usually fatal and is currently responsible for at least
15,000 deaths each year in the United States.4
Current efforts to limit the mortality from AAAs are
dependent on early detection and elective repair of the
diseased aorta. Extrapolation of AAA prevalence to US
census data indicates that aneurysm disease currently affects
at least 1.7 million individuals.5-7 Moreover, because of
changing demographics, the incidence rate of AAAs can be
expected to exceed 3 million as the Baby Boomers move
into their sixth decade.
Through numerous studies conducted during the past
decade, it has become clear that proteolytic degradation of
aortic structural proteins, especially elastin and collagen, is
responsible for initiation and expansion of AAAs. The
elastin and collagen degradation in aneurysm tissue is
caused by a family of endopeptidases called matrix metallo-
proteinases (MMPs). Several members of the MMP family
have been implicated in AAAs, including collagenase-1
(MMP-1), stromelysin-1 (MMP-3), the 72-kDa and 92-
kDa gelatinases (MMP-2 and MMP-9, respectively), mac-
rophage elastase (MMP-12), and collagenase-3 (MMP-
13).8,9
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During studies on the mechanisms of periodontitis in
diabetic rats, Golub and colleagues10 made the discovery
that tetracyclines have substantial metalloproteinase-inhib-
iting effects. In subsequent studies, they suggested that this
inhibition took place through a mechanism similar to that
found with the endogenous tissue inhibitors of metallopro-
teinases.11 Nonantibiotic chemically modified tetracyclines
have a similar efficacy to MMP inhibitors, which shows that
the MMP-inhibiting property of tetracyclines is unrelated
to their antimicrobial activity.12 Tetracyclines prevent ma-
trix degradation in many animal models of disease, and
because of their safety profile, they have been successfully
tested in several conditions associated with elevated MMP
activity and connective tissue destruction (eg, rheumatoid
arthritis,13 osteoarthritis, and periodontal disease11). Petri-
nec et al14 and Curci et asl15 first showed that doxycycline
can inhibit experimental AAAs in a rat model. These stud-
ies, however, used an extremely high dose of doxycycline
on a weight basis (30 mg/kg/day) in comparison with
standard antibiotic doses used in humans. This raised the
important question as to whether standard doses (200
mg/day) given to patients with AAA could achieve the
blood levels necessitated for aneurysm inhibition in animal
models. The purposes of this study were to determine the
dose response and serum doxycycline levels in a murine
model of AAA and to compare the effective serum levels in
the murine model with levels that could be obtained in
patients with AAA.
MATERIALS AND METHODS
Aneurysm induction model.16-18 Mice underwent
aneurysm induction or control operation according to a
protocol approved by the University of Nebraska Medical
Center Animal Care Committee. Mice (C576J/BL, Jack-
son Labs, Bar Harbor, Me) underwent anesthesia with
intraperitoneal 2,2,2-tribromomethanol and tert-Amyl al-
cohol (Avertin, Aldrich, Milwaukee, Wis) at the dose of
150 mg/kg. A laparotomy was performed, and the entire
infrarenal abdominal aorta was isolated from the surround-
ing retroperitoneal structures. The diameter of the aorta
was measured in triplicate to the nearest micrometer with a
video micrometer (Instruments for Physiology & Medi-
cine, Inc, San Diego, Calif). Diameter measurements were
taken at the area of maximal aortic diameter. To induce an
aneurysm, the aorta was bathed in 0.25 mol/L CaCl2 for
15 minutes, then rinsed with 0.9% NaCl. The abdomen was
closed in two layers. Ten weeks after the initial operation, a
laparotomy was repeated and the infrarenal aorta was iso-
lated and measured. The aortas of the mice that underwent
a sham operation were bathed in 0.9% NaCl solution in-
stead of CaCl2. The initial and final aortic diameters were
compared and expressed as median values. The presence of
an aortic aneurysm was defined as an increase in the aortic
diameter of greater than 50% of the original diameter.
Doxycycline preparation and treatment. Doxycy-
cline was prepared with doxycycline (Sigma Corp, St Louis,
Mo) dissolved in normal drinking water. The samples were
prepared in concentrations estimated to provide 0 mg/kg
(control), 10 mg/kg, 50 mg/kg, and 100 mg/kg daily on
the basis of the average C576J/BL mouse water intake.
The drinking water was placed in bottles shielded from all
light. The water was changed every other day. Doxycycline
treatment began immediately after aneurysm induction in
the mice. Ten mice were included in each group.
Measurement of serum doxycycline levels in mice.
Venous blood was drawn from the tail veins of the mice 5
weeks after aneurysm induction and at death. The blood
was centrifuged, aliquotted into 500-L cryovials, and
stored at70°C. The serum concentrations were measured
with reverse-phase high performance liquid chromatogra-
phy with ultraviolet detection.19,20
Human subjects and doxycycline treatment. Pa-
tients undergoing observation for AAAs ranging from 3.0
to 5.5 cm were invited to participate in a 6-month pilot trial
and underwent treatment with doxycycline (100 mg twice
daily). The compatibility of doxycycline with the patient’s
current medications was analyzed. Patients were recruited
from the University of Nebraska Medical Center and Meth-
odist Hospital after approval of the experimental protocol
by the Institutional Review Board at the University of
Nebraska Medical Center and Methodist Hospital. Plasma
doxycycline levels were drawn after 3 months and 6 months
of treatment.
Measurement of plasma doxycycline levels in pa-
tients with abdominal aortic aneurysm. Plasma samples
were obtained at follow-up office visits; however, no con-
certed effort was made to obtain these samples at a specific
time interval after the last dosing. Peripheral venous blood
was drawn into vacuum glass tubes containing ethylenedi-
amine tetraacetic acid and centrifuged. The plasma samples
were aliquotted into 1-mL cryovials and stored at 70°C.
One aliquot was used for measurement of the plasma
doxycycline concentration. Plasma concentrations were
measured with reverse-phase high performance liquid chro-
matography with ultraviolet detection.19,20
Relationship between serum levels and plasma lev-
els of doxycycline. Serum concentrations of doxycycline
were measured in mice, and plasma concentrations were
determined in the patients with AAA. To determine the
comparability of serum and plasma doxycycline levels, both
were drawn and measured simultaneously in eight mice.
The doxycycline measurements in the plasma and serum in
the mouse did not differ. With this information, the plasma
levels of patients and the serum levels of the doxycycline-
treated mice were inferred to be comparable.
Gelatin zymography. Aortic proteins were extracted
as previously described.14 Samples standardized for protein
concentration were resolved with nondenaturing electro-
phoresis through a 10% sodium dodecylsulfate-polyacryl-
amide gel copolymerized with 0.8% gelatin. The molecular
sizes of gelatinolytic activities were determined with
prestained protein standards (Bio-Rad Laboratories, Her-
cules, Calif). The gel was washed with buffer (2.5% Triton
X-100, 50 mmol/L Tris pH 7.5, 5 mmol/L CaCl2, 1
mol/L ZnCl2, and 0.02% NaN3) to remove sodium
dodecylsulfate and incubated overnight in substrate buffer
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(50 mmol/L Tris pH 7.5, 5 mmol/L CaCl2, 1 mol/L
ZnCl2, and 0.02% NaN3) at 37°C. After staining with
0.25% Coomassie brilliant blue R-250, gelatinolytic activity
was observed as clear bands against a dark background of
intact gelatin substrate.
Statistical analysis. Paired, nonparametric testing was
done with the Mann-Whitney test. The percentage increase
in aortic diameter among the four groups was assessed with
the Kruskal-Wallis test, and post hoc analysis was done with
a Mann-Whitney test, taking into account the Bonferroni
correction.
RESULTS
Serum doxycycline levels. The serum doxycycline
levels increased in a dose-dependent manner on the basis of
the concentration of the drug delivered in the drinking
water. The mean serum doxycycline levels in the mice with
each dose of doxycycline was 1.4  0.3 g/mL (10 mg/
kg), 2.7  0.4 g/mL (50 mg/kg), and 11.9  1.1
g/mL (100 mg/kg) (Fig 1). The serum doxycycline
levels achieved in these animal studies were in the same
range as those seen in patients with AAA with doxycycline
treatment (100 mg twice daily; Fig 1).
Abdominal aortic aneurysm suppression in the
mouse. Animals treated with doxycycline showed a dose-
dependent attenuation in the progression of aneurysmal
dilatation. The 10 mg/kg, 50 mg/kg, and 100 mg/kg
doses accounted for a 33%, 44%, and 66% reduction in
aneurysmal growth, respectively. The amount of aortic
dilatation was statistically significant (P  .05) when com-
pared with the baseline measurements in all four groups (0,
10, 50, and 100 mg/kg). The 50 mg/kg and the 100
mg/kg treatment groups both exhibited a statistically sig-
nificant attenuation in aortic dilatation when compared
with the control group (0 mg/kg). The 100 mg/kg treat-
ment group showed a significant inhibition of growth when
compared with each of the three other treatment groups.
The decrease in aneurysm growth in the 10 mg/kg treat-
ment group did not reach significance in comparison with
the control group (0 mg/kg doxycycline).
Correlation of serum values with aortic aneurysm
growth inhibition. As the serum level of doxycycline was
increased with an increasing oral dose, the degree of atten-
uation of AAA growth increased. The largest degree of
growth inhibition was clearly in the 100 mg/kg treatment
group (Fig 2). Importantly, the serum levels achieved in the
10 mg/kg and 50 mg/kg treatment groups were within
the range of the plasma levels achieved in humans with 100
mg of doxycycline twice daily (Fig 1).
Plasma doxycycline levels in patients with abdomi-
nal aortic aneurysms. Patients who underwent treatment
with doxycycline (100 mg twice daily) had a mean plasma
concentration of 4.14 g/mL, with a range of 1.8 g/mL
to 9.4 g/mL. The values are in the same range as those
that effectively inhibited AAA growth in the mouse.
Gelatin zymography. Gelatin zymography was per-
formed on the mouse aortas after harvest at 10 weeks. One
aorta from each of the doxycycline treatment groups was
included. Visualization of the gel shows a graduated de-
crease in the MMP-9 levels as the doxycycline treatment
dose was increased. The MMP-2 showed no change with
respect to the doxycycline treatment dose. However, the
MMP-2 levels in the mouse aorta should be at baseline
levels at 10 weeks after aneurysm induction (the time of
harvest). Thus, this result is not surprising (Fig 3).
DISCUSSION
The treatment of small AAAs is one of the most vexing
issues in vascular surgery. One treatment strategy for small
AAAs uses watchful waiting until the aneurysm reaches a
size where the risk of continued observation exceeds the
risk of surgical intervention. This approach may unfortu-
Fig 1. Serum doxycycline concentration measurements in mice with three different oral doses of doxycycline and in
control group shown in comparison with plasma doxycycline measurements in patients with AAAs.
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nately create significant anxiety for the patient and family.
As the pathophysiology of AAA has begun to unfold, it has
become clear that MMP overexpression may play a crucial
role in the genesis and progression of this disease. The
concept of pharmacologic inhibition of MMPs has gained
significant attention as one of the first potential medical
treatments for small AAAs.14,15,21,22 A substantial effort
towards the investigation of doxycycline (a nonspecific
MMP inhibitor) as a means to inhibit AAA growth began
after Petrinec et al14 showed that aneurysm expansion
could be inhibited in a rodent model of AAA. One concern,
however, was that the doses of doxycycline used (30 mg/
kg/day) in the study greatly exceeded standard antibiotic
doses (2 to 3 mg/kg/day). Therefore, one of the primary
starting points for the investigation of doxycycline in hu-
mans with small AAAs was whether the circulating levels of
doxycycline necessary to inhibit AAA progression in animal
models could be safely achieved in patients.
In our murine model, we show a dose-dependent inhi-
bition of aneurysm enlargement with doxycycline. The
serum levels present in the mice allowed for a 33% to 66%
reduction in aortic growth. These serum levels were com-
parable with the plasma levels achieved in human subjects
with 100 mg of doxycycline twice daily. The achievement
of at least a 40% inhibition of normal AAA growth could
have great clinical significance. For example, a 40% reduc-
tion of aneurysm growth in a 3.5-cm aneurysm would add
3.1 years to the average time between detection and the
aneurysm reaching 5.5 cm (Fig 4). This would impact
patients in several ways because age, comorbidities, and
cardiovascular disease in patients with AAA contribute to
the 6% to 7% yearly mortality rate in these patients.3 Most
patients with small AAAs die from coronary artery disease,
stroke, and cancer, rather than aneurysm rupture. Second,
effective medical treatment could lead to increased screen-
ing for AAAs. Finally, a proven medical therapy for AAA
would lead to testing of other agents, which may have even
greater efficacy. As the efficacy of inhibition increases, the
percentage of patients dying from other causes before
reaching the 5.5-cm threshold increases.
Fig 2. Effects of different doses of oral doxycycline on aneurysm inhibition in murine model (aortic diameter on left
axis) and relationship to serum doxycycline levels (right axis). Treatment groups of 50 mg/kg and 100 mg/kg showed
statistically significant attenuation in aortic growth when compared with control group (0 mg/kg). *P  .05.
Fig 3. Zymogram shows expression of latent and active forms of MMP-2 and MMP-9 with increasing doses of
doxycycline.
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This study does not assess the mechanism of action of
the tetracyclines, although it is assumed to be related to the
ability of doxycycline to nonspecifically inhibit MMPs, as
noted in our zymograms. The precise mechanism of action
is not yet entirely clear, and doxycycline has other poten-
tially important effects, such as attenuating the immune
response through its effect on lymphocytes.23 However,
this study provides a baseline regarding the circulating
levels of doxycycline necessary to inhibit AAA expansion.
Importantly, the plasma levels achieved in patients with
AAA with 100 mg of doxycycline twice daily was in the
range shown to inhibit aneurysm progression in our murine
model. Although the mg/kg dose of doxycycline given the
mice was substantially higher than doses given to humans,
the steady state levels of doxycycline were comparable
because of the rapid metabolism of doxycycline in mice.
Thus, the steady state level necessary to achieve inhibition
of aneurysm growth in mice is achievable in patients with
AAA. Furthermore, this study shows a correlation between
the plasma levels and the degree of aneurysmal inhibition.
As the number of individuals at risk for AAA steadily
increases, the impact of this disease will climb with respect
to mortality and financial impact on an already beleaguered
healthcare system. Presently, no medical treatment exists to
inhibit the growth of small aneurysms, and the only effec-
tive option to protect against rupture is repair. If a medical
option existed, it could lead to the screening, detection,
and medical treatment of small aneurysms. The need for
surgical intervention could be potentially obviated in some
patients. Screening also would have an immediate impact
on mortality, with identification of those large undetected
aneurysms at significant risk of rupture.
Detection of a small aneurysm raises a considerable
dilemma, in that the natural history of small AAAs is one of
gradual expansion (at an average rate of 10% per year) and
eventual rupture. Because no proven medical interventions
capable of suppressing aneurysm growth exist, the detec-
tion of small AAAs only leads to the need for serial mea-
surements of aneurysm size until repair is indicated. This
approach is particularly unsettling given that aneurysms
grow in an unpredictable fashion and the biologic factors
influencing aneurysm expansion are incompletely under-
stood. The absence of medical interventions with which to
treat the large number of patients with small AAAs has
diminished enthusiasm for ultrasound scan screening pro-
grams on the basis of cost. Clearly, however, better ap-
proaches will be needed during the next decade for the
evaluation and management of patients with small asymp-
tomatic AAAs.
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DISCUSSION
Dr Gilbert Upchurch (Ann Arbor, Mich). I was asked to
review this article, and I thank you for giving me the manuscript in
adequate time to be able to do that. As you have elucidated,
previous work by Thompson and others has suggested that treat-
ment of rats with doxycycline leads to a decrease in aneurysm
growth. Previous animal work suffers primarily from superphysi-
ologic doses of doxycycline that really would not correlate with
anything that we would see in humans. In the present study, you
have basically shown that increasing doses of doxycycline in the
calcium chloride murine model of aortic aneurysms leads to a
decrease in aneurysm growth with increasing serum concentrations
of doxycycline. I have three questions.
The first question is related to the model. The group from
Northwestern has recently documented that in this same model
they get aneurysms to occur as early as 3 weeks, and I also noticed
in the manuscript that your aneurysm group did not reach 11⁄2
times your control group at 10 weeks. My first question has to do
with variability in the model.
The second question has to do with the human portion of the
study. You showed that there was a wide range of doxycycline
levels among the human patients, and I was wondering if you had
any correlation between decrease in aneurysm growth and doxy-
cycline levels.
My third question has to do with doxycycline as a general
inhibitor of MMPs. I wonder if you had any preliminary data or
could you even speculate as to which MMPs might be affected, as
I know that 2, 9, and 12 are felt to be key. I wonder if you had done
enzyme-linked immunosorbent assays or RT-PCRs or something.
I really applaud your work, and I hope that the National
Institutes of Health is taking notice and may in fact fund this large
multicenter trial. Thank you.
Dr Mathew Longo. Thank you for the questions, Dr Up-
church. The initial question regards variability in the mouse model
in Dr Pierce’s studies, and they reported their data after sacrificing
the mice 3 weeks after aneurysm induction. What we found initially
in our studies, and we have done a rather sizable population now of
mice where we have induced aneurysms, is that we would continue
to get aneurysm growth on out to about the 8-week to 10-week
time period, and we were relatively confident that we would get a
plateau in aneurysm growth rates after 10 weeks. Thus, we choose
to carry all of our experiments out to that time point, where we
know we can achieve a plateau in the aneurysm growth rates. Also,
we were able to determine that we had a great deal of variability
when we sacrifice at much earlier time points. So, we do not have
a very good explanation for the large amount of variability, but by
about 10 weeks, we were able to get relatively consistent increases
in aortic diameter. So, we choose to sacrifice at that time point.
With respect to our mice not getting a 1.5% increase over the
control rates, when we looked at the mice that we sacrifice in our
control group, the histologic data and size data were consistent
with what we saw in earlier studies where we had induced aneu-
rysms using the calcium chloride model. So, we were relatively
confident that the control group was the same as what we had
previously done.
With regard to the human patients and whether or not we saw
that higher serum levels correlated with a decrease in aneurysm
growth rates in our pilot study, what we did note is that there was
roughly a 2-mm increase in aortic diameters when we would scan
them at 6 months and this would be lower than the expected rate
in patients not treated with doxycycline. However, we were not
able to show a correlation between the serum levels and the actual
rates of increase in the aortas.
With regard to the final question, speculation of what the
action of doxycycline might do with the matrix metalloproteinases,
we were able to show with zymography that we got decreased
levels of matrix metalloproteinase-2 and matrix metalloprotein-
ase-9, which would be consistent with the generalized effects of
doxycycline. We have not looked at matrix metalloproteinase-12 in
our laboratory yet to determine what the expression rates of that
are in the doxycycline mice.
Thank you very much.
Dr William Turnipseed (Madison, Wis). First, a very articu-
late presentation, but whether this is good science or not I do not
know. In a sense, it redefines the whole title “Of mice and men.”
To begin with, I really have a hard time correlating your aneurysm
model with what goes on in humans with atherosclerosis. It also
reminds me of a story about a student whose science project was
presented before his class. It was about a frog he taught to jump on
command. He decided to test the frog’s response to successive
limb amputations. The frog struggled to jump as each limb was
removed. When the last limb was gone, he would not jump
anymore. The teacher asked the student what he concluded from
his experiment. He said, “Well, my conclusion is, upon amputation
of all four limbs, the frog goes deaf.” In this case, we have focused
on the idea that MMP is being affected by an antibiotic. There is a
lot of literature that would suggest that infectious organisms, such
as Chlamydia, may affect aneurysm size and growth and affect
morbidity, mortality, myocardial infarction, and/or stroke. You
used an antibiotic that supposedly has a drug effect on inflamma-
tory mediators, but have you evaluated any patients or animals for
antibiotic titers? Have you cultured arteries to see whether there
are bacteria growing in them? Do you think the effect of the
antibiotic might alter bacterial contamination in these vessels and
cause this response?
Dr Longo. Thank you for the question, Dr Turnipseed.
There is no question that doxycycline has a number of different
actions that could potentially all work to inhibit aneurysm growth.
We have chosen to focus on the matrix metalloproteinase aspect as
research began to be published on matrix metalloproteinase and
tetracyclines in the early 1990s with respect to periodontal disease,
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various forms of cancer, rheumatoid arthritis, and osteoarthritis,
and we have kind of taken some of the principles from that early
research and applied them to the area of vascular surgery. Some of
the initial work on that was done by Golub and his associates out in
New York and their demonstration that inhibiting metalloprotein-
ases could in fact alter the progression of disease, and we kind of
took off a little bit from there. Some of the other actions of
doxycycline or any of the tetracyclines would certainly be an effect
on the immune system and effect on lymphocytes. That could
certainly play a role in aneurysm inhibition as we all know that
there is a rather large inflammatory response than is necessary for
aneurysm progression. There are other thoughts that the tetracy-
clines might inhibit nitric oxide levels, which then could subse-
quently affect the role of the endothelial cells of the aneurysm. We
really have not looked at the antibiotic properties with respect to
homogenizing aortas and then trying to grow out some bacteria
from them and whether or not the tetracyclines would have an
effect on that. With respect to the actual action of doxycycline
matrix metalloproteinases, that is still left to be determined. We are
still trying to work out the exact mechanism on which it works, and
that investigation is being continued both in our lab as well as
several other labs around the country.
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